On May 5, 2020, BARDA Director Rick Bright filed a whistleblower complaint alleging that Health and Human Services officials retaliated against him after he warned about the coronavirus threat, opposed politically promoted treatments, and pressed for scientifically supported spending of billions of dollars in congressional pandemic funds. Bright said he resisted additional support for Ridgeback Biotherapeutics’ molnupiravir program until more safety data were available, and objected to off-label hydroxychloroquine promotion, which he characterized as political cronyism rather than evidence-based policy.
Bright had been reassigned to the National Institutes of Health on April 20, 2020, a move HHS described as work on point-of-care testing but Bright called a retaliatory demotion. On May 7, the U.S. Office of Special Counsel found reasonable grounds to believe HHS had unlawfully retaliated against him and recommended reinstatement as BARDA chief; the recommendation was nonbinding and he was not restored. At a May 14 House hearing, Bright warned that inadequate coordination could produce a prolonged national disaster and said lives may have been lost. He submitted an involuntary resignation on October 6, 2020, alleging he had been given no meaningful work and that testing proposals were rejected for political reasons. The supplied account records no final judicial finding against the administration.
